Moderna company profile
Company profile
Moderna has 4,700 employees and is headquartered in Cambridge, United States.
Moderna, Inc., a biotechnology company with 4,700 employees, develops messenger RNA medicines for markets in the United States, Europe and other regions. Its respiratory vaccines include COVID, RSV and seasonal influenza products under the Spikevax and mRESVIA names, while its portfolio also covers latent virus vaccines against cytomegalovirus and Epstein-Barr virus, public health vaccines against Zika, Nipah and Mpox, oncology therapeutics such as intismeran autogene, and rare disease treatments for propionic and methylmalonic acidemia and cystic fibrosis. Its collaborators include Merck & Co., Vertex Pharmaceuticals, the Bill & Melinda Gates Foundation and OpenAI.
Moderna is headquartered in Cambridge, Massachusetts, and was founded in 2010. It changed its name from Moderna Therapeutics in August 2018. In the fiscal year ended December 2025, revenue was USD 1.9 billion, down 39.9% from the previous year, and the company posted a net loss of USD 2.8 billion. By region, the United States accounted for 61.7% of revenue, the rest of the world for 35.6% and Europe for 2.7%.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Headquarters
- 325 Binney Street, 02142, Cambridge
- Employees
- 4,700
- Chief executive
- Stéphane Bancel
- Founded
- 2010
- Fiscal year
- January - December
- Listing
- MRNA · NASDAQ
- Indices
- Nasdaq 100S&P 500
- Currency
- USD
- ISIN
- US60770K1079
- Website
- modernatx.com
Moderna and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| ModernaMRNA | United States | $90.38B | 4,700 | -80.8% | — |
| Regeneron PharmaceuticalsREGN | United States | $98.84B | 15,410 | 30.4% | 21.1 |
| argenxARGX | United States | $60.37B | 1,863 | 31.9% | 33.3 |
| Vertex PharmaceuticalsVRTX | United States | $136.56B | 6,400 | 37.8% | 34.7 |
| BeOne MedicinesONC | United States | $47.58B | 12,000 | 17.8% | 53.4 |
| Royalty PharmaRPRX | United States | $39.85B | 100 | 64.4% | 45.3 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
